Encenicline clinical trials
Also written EVP-6124 and MT-4666.
How each study uses encenicline is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2013 (5)
| Year | Studies |
|---|---|
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 1
FORUM Pharmaceuticals Inc (13) · Mitsubishi Tanabe Pharma Corporation (2) · A. Eden Evins (1)
Studies
Open first, then newest update. How each study uses encenicline is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 16
- A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine DependenceTerminatedPhase 2A. Eden EvinsNCT01480232Written as EVP-6124How we know
- A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyCompletedPhase 3FORUM Pharmaceuticals IncNCT01714713Written as EVP-6124How we know
- Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyCompletedPhase 3FORUM Pharmaceuticals IncNCT01716975Written as EVP-6124How we know
- Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic TherapyCompletedPhase 3FORUM Pharmaceuticals IncNCT01714661Written as EVP-6124How we know
- Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025TerminatedPhase 3FORUM Pharmaceuticals IncNCT02004392Written as EVP-6124How we know
- Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's DiseaseTerminatedPhase 3FORUM Pharmaceuticals IncNCT01969136Written as Drug: EVP-6124How we know
- Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's DiseaseTerminatedPhase 3FORUM Pharmaceuticals IncNCT01969123Written as Drug: EVP-6124How we know
- Safety Study of MT-4666 in Subjects With Alzheimer's DiseaseTerminatedPhase 3Mitsubishi Tanabe Pharma CorporationNCT02327182Written as MT-4666How we know
- Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving MemantineWithdrawnPhase 2FORUM Pharmaceuticals IncNCT02246075Written as EVP-6124How we know
- Safety and Efficacy of MT-4666CompletedPhase 2Mitsubishi Tanabe Pharma CorporationNCT01764243Written as MT-4666How we know
- EVP-6124 Renal Impairment StudyCompletedPhase 1FORUM Pharmaceuticals IncNCT01984723Written as Experimental: EVP-6124How we know
- EVP-6124 Hepatic Impairment StudyCompletedPhase 1FORUM Pharmaceuticals IncNCT01984736Written as Experimental: EVP-6124How we know
- Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's DiseaseCompletedPhase 2FORUM Pharmaceuticals IncNCT01073228Written as EVP-6124How we know
- Safety and Cognitive Function Study of EVP-6124 in Patients With SchizophreniaCompletedPhase 2FORUM Pharmaceuticals IncNCT00968851Written as EVP-6124How we know
- Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With SchizophreniaCompletedPhase 1FORUM Pharmaceuticals IncNCT01556763Written as EVP-6124 (0.3 mg/day)How we know
- Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's DiseaseCompletedPhase 1FORUM Pharmaceuticals IncNCT00766363Written as EVP-6124 (0.1 mg/day)How we know
Codes
What other systems call encenicline · ClinicalTrials.gg INT006100
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q19904062 | encenicline | One source Wikidata |
| NCI Thesaurus | C166844 | Encenicline | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.